FLOATER PROTECT MULTI AKTIENANLEIHE - NOVO-NORDISK B/ELI LILLY & CO | Market Closed - Börse Stuttgart 02:10:50 2024-05-17 am EDT | ||
| 102.2 EUR | -0.59% |
|
| Current month | +1.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 102.2 | -0.59% |
| 24-05-16 | 102.8 | +0.29% |
| 24-05-15 | 102.5 | +0.34% |
| 24-05-14 | 102.2 | +1.10% |
| 24-05-13 | 101.1 | -0.26% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 02:10 am EDT
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD3FD8 |
| ISIN | DE000VD3FD85 |
| Date issued | 2024-04-22 |
| Strike | 731.3 $ |
| Maturity | 2025-06-20 (398 Days) |
| Parity | 0.73 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | both |
| Currency | EUR |
Technical Indicators
| Highest since issue | 102.8 € |
|---|---|
| Lowest since issue | 99.07 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Certificat
